| Market Cap | 37.49M | P/E | - | EPS this Y | 35.00% | Ern Qtrly Grth | - |
| Income | -30.01M | Forward P/E | -1.20 | EPS next Y | 12.30% | 50D Avg Chg | -36.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -33.00% |
| Dividend | N/A | Price/Book | 1.87 | EPS next 5Y | - | 52W High Chg | -68.00% |
| Recommedations | 2.00 | Quick Ratio | 3.95 | Shares Outstanding | 43.29M | 52W Low Chg | 24.00% |
| Insider Own | 15.97% | ROA | -56.81% | Shares Float | 24.46M | Beta | -0.01 |
| Inst Own | 37.38% | ROE | -125.90% | Shares Shorted/Prior | 51.61K/21.44K | Price | 1.26 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 303,670 | Target Price | 7.90 |
| Oper. Margin | - | Earnings Date | - | Volume | 217,031 | Change | -3.82% |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
| HC Wainwright & Co. | Buy | Apr 10, 24 |
| Laidlaw & Co. | Buy | Mar 18, 24 |
| HC Wainwright & Co. | Buy | Mar 15, 24 |
| JonesTrading | Buy | Mar 13, 24 |
| HC Wainwright & Co. | Buy | Nov 13, 23 |
| HC Wainwright & Co. | Buy | Aug 11, 23 |
| EF Hutton | Buy | Jun 5, 23 |
| HC Wainwright & Co. | Buy | May 16, 23 |
| HC Wainwright & Co. | Buy | Apr 26, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director Director | Dec 12 | Buy | 2.48 | 75,001 | 186,002 | 570,724 | 12/13/22 |
| Fletcher Aaron G.L. | Director Director | Dec 12 | Buy | 2.48 | 75,001 | 186,002 | 570,724 | 12/13/22 |
| Fletcher Aaron G.L. | Director Director | Sep 28 | Buy | 2.02 | 25,000 | 50,500 | 561,989 | 09/29/22 |
| Kreis Leslie W. | Director Director | Sep 28 | Buy | 2.02 | 25,000 | 50,500 | 561,989 | 09/29/22 |
| Fletcher Aaron G.L. | Director Director | Aug 26 | Buy | 2.02 | 51,214 | 103,452 | 559,076 | 08/30/22 |
| Kreis Leslie W. | Director Director | Aug 26 | Buy | 2.02 | 51,214 | 103,452 | 559,076 | 08/30/22 |
| Kreis Leslie W. | Director Director | Aug 17 | Buy | 1.93 | 50,000 | 96,500 | 553,110 | 08/18/22 |
| Fletcher Aaron G.L. | Director Director | Aug 17 | Buy | 1.93 | 50,000 | 96,500 | 553,110 | 08/18/22 |
| Kreis Leslie W. | Director Director | Aug 16 | Buy | 1.9 | 1,773,684 | 3,370,000 | 540,287 | 08/17/22 |
| Fletcher Aaron G.L. | Director Director | Aug 16 | Buy | 1.9 | 1,773,684 | 3,370,000 | 540,287 | 08/17/22 |